One of the long standing problems in Amyotrophic Lateral Sclerosis is the absence of biomarkers. Technology is advancing where patients can cause some of their biometrics to accumulate as data on their computers with minute by minute vigilance and, well, while these reports are unclear on the issue of accuracy, the precision of the data produced by these techniques does not appear in these reports as near as I can tell, some data would be better than no data. The tell tail sign of Amyotrophic Lateral Sclerosis affliction is the discovery of intracellular Bunina bodies in the patient's motor neurons, which can only be done in an Amyotrophic Lateral Sclerosis autopsy (permissible only one patients who have died). The best intel obtainable today from patients is available through the β-phragm pacing device, which can avail continuous electromyogram stream from equipped patients and thereby show the activity of the nearby synapses. At present I know of only one journal paper showing β-phragmatic electromyogram intel from the pacing device . . . hopefully there are and will be more.

Here are several papers showing automatic electronic data acquisition possibly usable in Amyotrophic Lateral Sclerosis patients.


Finger wrap uses sweat to provide health monitoring at your fingertips--literally
Finger wrap uses sweat to provide health monitoring at your fingertips--literally | ScienceDaily

New tech aims to monitor health from your fingertip
https://www.msn.com/en-us/health/oth...d=BingNewsSerp

A fingertip-wearable microgrid system for autonomous energy management and metabolic monitoring
A fingertip-wearable microgrid system for autonomous energy management and metabolic monitoring | Nature Electronics

Diaphragm motor responses to phrenic nerve stimulation in ALS: Surface and needle recordings
Diaphragm motor responses to phrenic nerve stimulation in ALS: Surface and needle recordings - PubMed

It surprises me researchers are so passive regarding this issue.

Thanks for this info!

I wonder if researchers' passivity has to do with the lack of cure for ALS, and, therefore, no reason to get an early warning.

But maybe I'm wrong about efficacy of treatment. I've been out-of-the-loop for so long.

Interesting argument, although the biggest obstacle is the rareness of the syndrome, the biomarker deficiencies most strongly make early warning almost impossible. Only fALS patients seem to know 'fast:' in most cases because they are very familiar with the disorder.

The best efficacy claims are related to the pacer but the intervention timing is fairly critical for getting near maximum benefit.